Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))

R. Campo; E. DeJesus; U. F. Bredeek; K. Henry; H. Khanlou; K. Logue

doi:10.1093/cid/cit417

Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))

R. Campo
, E. DeJesus
, U. F. Bredeek
, K. Henry
, H. Khanlou
, K. Logue

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	779
Number of pages	1
Journal	Clinical Infectious Diseases
Volume	57
Issue number	5
DOIs	https://doi.org/10.1093/cid/cit417
State	Published - Sep 1 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1093/cid/cit417

Find It

Find It at U of M Libraries

Cite this

Campo, R., DeJesus, E., Bredeek, U. F., Henry, K., Khanlou, H., & Logue, K. (2013). Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45)). Clinical Infectious Diseases, 57(5), 779. https://doi.org/10.1093/cid/cit417

Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45)). / Campo, R.; DeJesus, E.; Bredeek, U. F. et al.
In: Clinical Infectious Diseases, Vol. 57, No. 5, 01.09.2013, p. 779.

Research output: Contribution to journal › Comment/debate › peer-review

Campo, R, DeJesus, E, Bredeek, UF, Henry, K, Khanlou, H & Logue, K 2013, 'Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))', Clinical Infectious Diseases, vol. 57, no. 5, pp. 779. https://doi.org/10.1093/cid/cit417

Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K. Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45)). Clinical Infectious Diseases. 2013 Sep 1;57(5):779. doi: 10.1093/cid/cit417

Campo, R. ; DeJesus, E. ; Bredeek, U. F. et al. / Erratum : SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45)). In: Clinical Infectious Diseases. 2013 ; Vol. 57, No. 5. pp. 779.

@article{d93b88a9adb049e3a14c5a7f2d917521,

title = "Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))",

author = "R. Campo and E. DeJesus and Bredeek, \{U. F.\} and K. Henry and H. Khanlou and K. Logue",

year = "2013",

month = sep,

day = "1",

doi = "10.1093/cid/cit417",

language = "English (US)",

volume = "57",

pages = "779",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Erratum

T2 - SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))

AU - Campo, R.

AU - DeJesus, E.

AU - Bredeek, U. F.

AU - Henry, K.

AU - Khanlou, H.

AU - Logue, K.

PY - 2013/9/1

Y1 - 2013/9/1

UR - https://www.scopus.com/pages/publications/84881438476

UR - https://www.scopus.com/pages/publications/84881438476#tab=citedBy

U2 - 10.1093/cid/cit417

DO - 10.1093/cid/cit417

M3 - Comment/debate

AN - SCOPUS:84881438476

SN - 1058-4838

VL - 57

SP - 779

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

UN SDGs

Publisher link

Find It

Other files and links

Cite this